ASH Annual Meeting 2020
Advertisement
DocWire News spoke with Parameswaran Hari, MD, Chief of Hematology/Oncology at the Medical College of Wisconsin, about ...
According to data presented at the 2020 American Society of Hematology Annual Meeting & Exposition, the use of ...
The all-virtual 62nd ASH Annual Meeting & Exposition highlighted some of the newest data about Venclexta. DocWire ...
During the all-virtual 62nd ASH Annual Meeting & Exposition, Michael U. Callaghan, MD, Associate Professor of ...
Sickle cell disease (SCD) shortens life expectancy and leads to morbidity. Recent advancements in allogeneic ...
Alpha-globin mutations are common, and the number and type of mutated alleles will determine the severity of subsequent ...
At the all-virtual 62nd ASH Annual Meeting & Exposition, researchers presented data from an ongoing phase I/II trial ...
Chimeric antigen receptor (CAR) T-cell therapy holds much promise in treating B-cell malignancies and multiple myeloma. ...
Findings presented at the 2020 American Society of Hematology Annual Meeting & Exposition suggest that ejection ...
A regimen of ixazomib, cyclophosphamide, and dexamethasone produced hematologic responses in 57% of patients with ...
In younger patients with mantle cell lymphoma (MCL), pre-transplant MRD status in both bone marrow and peripheral blood ...
Treatment with zanubrutinib was well tolerated and associated with high clinical activity in patients with ...
A novel idiotype (scFv-CCL20) DNA vaccine was associated with favorable perturbation of the immune microenvironment in ...
A study has found that the addition of rituximab to ixazomib, when used as maintenance therapy following autologous ...
A first-line regimen consisting of once-daily ibrutinib plus venetoclax was associated with high rates of undetectable ...
Early initiation of Bruton’s tyrosine kinase inhibitor zanubrutinib in patients with chronic lymphocytic leukemia ...
Individuals with light-chain (AL) amyloidosis have higher odds of severe SARS-CoV-2 infection or mortality compared with ...
Therapy with isatuximab for previously treated light-chain (AL) amyloidosis was found to be effective and safe, ...
Hypomethylating agents (HMAs) are the current standard of care in patients with high-risk myelodysplastic ...
Many patients with myelodysplastic syndromes (MDS) are dependent on blood transfusions. Therefore, sufficient blood ...
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.